U.S. Central Nervous System Therapeutic Market Size & Outlook
U.S. central nervous system therapeutic market, 2018-2028 (US$M)
Related Markets
U.S. central nervous system therapeutic market highlights
- The U.S. central nervous system therapeutic market generated a revenue of USD 50,467.5 million in 2020 and is expected to reach USD 84,106.4 million by 2028.
- The U.S. market is expected to grow at a CAGR of 6.6% from 2021 to 2028.
- In terms of segment, neurodegenerative diseases was the largest revenue generating disease in 2020.
- Neurodegenerative Diseases is the most lucrative disease segment registering the fastest growth during the forecast period.
Central nervous system therapeutic market data book summary
| Market revenue in 2020 | USD 50,467.5 million |
| Market revenue in 2028 | USD 84,106.4 million |
| Growth rate | 6.6% (CAGR from 2020 to 2028) |
| Largest segment | Neurodegenerative diseases |
| Fastest growing segment | Neurodegenerative Diseases |
| Historical data | 2018 - 2019 |
| Base year | 2020 |
| Forecast period | 2021 - 2028 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Neurovascular Diseases, CNS Trauma, Mental Health, Neurodegenerative Diseases, Infectious Diseases, CNS Cancer |
| Key market players worldwide | Biogen Inc, Otsuka Pharmaceutical, Eli Lilly and Co, Merck & Co Inc, AstraZeneca PLC, Novartis AG ADR, Teva Pharmaceutical Industries Ltd, Johnson & Johnson, Pfizer Inc |
Other key industry trends
- In terms of revenue, U.S. accounted for 47.6% of the global central nervous system therapeutic market in 2020.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2028.
- In North America, U.S. central nervous system therapeutic market is projected to lead the regional market in terms of revenue in 2028.
- Canada is the fastest growing regional market in North America and is projected to reach USD 5,669.5 million by 2028.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Central Nervous System Therapeutic Market Scope
Central Nervous System Therapeutic Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. central nervous system therapeutic market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to central nervous system therapeutic market will help companies and investors design strategic landscapes.
Neurodegenerative diseases was the largest segment with a revenue share of 55.92% in 2020. Horizon Databook has segmented the U.S. central nervous system therapeutic market based on neurovascular diseases, cns trauma, mental health, neurodegenerative diseases, infectious diseases, cns cancer covering the revenue growth of each sub-segment from 2018 to 2028.
initiatives being undertaken by regulatory bodies to support the pharmaceutical companies in developing novel therapies is expected to drive the market on American Brain Foundation, the prevalence of CNS disorders. The U.S. FDA has designated CNS pharmaceutical berubicin as an orphan drug for treatment of malignant gliomas.
Reasons to subscribe to U.S. central nervous system therapeutic market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. central nervous system therapeutic market databook
-
Our clientele includes a mix of central nervous system therapeutic market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. central nervous system therapeutic market , including forecasts for subscribers. This country databook contains high-level insights into U.S. central nervous system therapeutic market from 2018 to 2028, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. central nervous system therapeutic market size, by disease, 2018-2028 (US$M)
U.S. Central Nervous System Therapeutic Market Outlook Share, 2020 & 2028 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
